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Dyslipidaemia is a treatable risk factor for atherosclerosis, and the 2011 National Heart, Lung and 
Blood Institute (NHLBI) guidelines recommend universal lipid screening at 9-11 years. This study 
aimed to assess the number of children with cardiovascular disease risk factors and parental 
attitudes regarding cholesterol screening and management.  
Methods 
Parents of children aged 3-14 years admitted to the paediatric wards at University Hospital Limerick 
received questionnaires over a 4-week period. Data collected included demographics, 
cardiovascular risk factors, and parental attitudes to lipid screening and management.  
Results  
A total of 53 parents completed the questionnaire survey and of those 40% (n=21) of patients met 
criteria for targeted screening, while 53% (n=30) met criteria for screening as per NHLBI guidelines. 
Restriction to those aged 9 and over resulted in 100% (n=26) being screened based on NHLBI 
guidelines with 38% (n=10) being screened using targeted screening. Ninety eight percent of 
respondents (n=52) had no objection to lipid analysis being performed.  
Conclusion 
A significant proportion of children would not be included with targeted screening that would be 
included on screening as defined by the NHLBI guidelines. Almost all the of study group had no 
issue with lipid testing being carried out and so may be an avenue for future intervention to help 
prevent development of cardiovascular disease.  
 




Dyslipidaemia is a risk factor for atherosclerosis, which is an early step in the development of 
cardiovascular disease (CVD) 1 2. The process of atherosclerosis begins in childhood and causes 
cardiovascular morbidity due to coronary artery disease, stroke, and peripheral arterial disease 3 4. In 
addition to dyslipidaemia, other risk factors for the development of atherosclerosis and CVD include 
obesity, hypertension, smoking, hyperglycaemia, and a positive family history of CVD. The severity of 
atherosclerotic plaques in adults correlates positively with the duration of the dyslipidaemia and as a 
result early intervention in children with dyslipidaemia has been recommended as a preventative 
therapy against CVD development, although the issue of screening and exact treatment remains 
controversial 5 6. 
In 2011 the National Heart, Lung and Blood Institute (NHLBI) Expert panel formulated guidelines for 
Cardiovascular health and risk reduction in children, recommending age-dependent universal 
screening for children between 9-11 years, as opposed to targeted screening, which had previously 
been recommended 7 8. These recommendation changes were considered the best method of 
identifying all children with severe dyslipidaemia and allow for the earliest treatment and follow-up 5 
6. The guidelines differ from the selective screening recommended of children and adolescents by the 
2007 US Preventive Services Task Force 4.  Screening variables in selective processes include, a positive 
family history of cardiovascular disease or dyslipidaemia, or where family history is unknown, any 
patient with any risk factor associated with CVD which include obesity, hypertension, diabetes, or 
tobacco usage. Recent studies have shown that screening only patients with risk factors fails to identify 
some patients with genetic or acquired dyslipidaemias 8. Addressing childhood dyslipidaemia is of 
significant public health importance due to the high mortality rate associated with CVD, and this is 
particularly true within the Irish population.  
We report a pilot questionnaire-based study, on a general paediatric in-patient population at 
University Hospital, Limerick (UHL). UHL is a university-affiliated regional paediatrics unit, serving a 
catchment area of approximately 1.1 million people. The aims of this study were to evaluate the 
incidence of CVD risk factors within a general paediatrics hospital inpatient population and to explore 
issues relating to parental concerns or barriers to undertaking universal screening for dyslipidaemia.  
 
Methods  
A questionnaire was designed based on the NHLBI Expert panel guidelines recommendations for 
paediatric lipid screening 7, and was formulated to investigate the number of cardiovascular risk 
factors within the patient cohort including; family history of CVD, tobacco exposure at home, self-
reported history of hypercholesterolaemia in parents, current diagnosis of diabetes mellitus, 
hypertension, or any other reported condition pre-disposing to secondary dyslipidaemia. Patient 
demographic data including age, height and weight was collected where possible. The questionnaire 
also examined specific questions regarding parental concerns to having additional blood samples 
taken for lipid analysis and also regarding willingness to attend a dietician for diet and lifestyle advice 
and additionally, if there were issues with the use of a lipid lowering medications.  
The questionnaire was validated, and a pilot-study was conducted on a sub-sample of the target 
population, with the questionnaire revised subsequently for any ambiguity.  
                                                      
 
 
Pilot data was excluded from the final analysis. The survey required an average of 5 minutes to 
complete.  This study was approved ethically by the University Hospital Limerick ethical committee. 
Inclusion criteria included: the ability to speak and understand English, parents being present at the 
time of interview and being admitted onto the paediatrics ward at UHL. Exclusion Criteria included: 
the inability to speak and understand English and where siblings had already participated in the study. 
Patients were not excluded on the basis of medical background. The lower limit of 3 years was chosen 
as screening is not recommended below this age, while the upper limit of 14 was chosen as this is the 
age limit for admission of newly diagnosed patients to the Paediatrics ward at UHL. 
The sample method consisted of systematically approaching the parents/guardians of patients who 
were inpatients within the Paediatrics ward at UHL over the course of the sampling period. The 
questionnaires were completed over a 4-week period in February 2015. Parental consent was 
obtained, and answers were self-reported.  The completed questionnaire data was coded into SPSS 
version 20 for further analysis. An overall summary of the questionnaire data was analysed, and 
summary data compiled.  
 
Results 
Number of questionnaires 
A total of 66 patients fulfilling the inclusion criteria were admitted during the study period, of whom 
63 consented to participate and 3 declined. Fully completed questionnaires were returned by 53/63 
parents/guardians (84%). The majority (over 75%) of the questionnaires were returned without a 
weight or height recorded and as a result BMI was not recorded as the questionnaire was anonymous 
and these variables could not be added later.  
Description of risk factors 
Twenty-one (40%) of those surveyed had at least one CVD risk factor, while 60% (n=32) had no 
cardiovascular disease risk factor (Fig. 1).  Of the 53 patients, 28% (n=15) had a family history of CVD, 
9% (n=5) had a parent/guardian with a previous diagnosis of dyslipidaemias, 8% (n=4) patients had 
type 1 diabetes mellitus (T1DM) and 30% (n=16) lived with someone who smoked within the home 
(Fig. 2).  
Children who would fulfil screening guidelines as per 2011 NHLBI guidelines: 
Eleven (40%; n= 11/27) of patients below the age of 9 years fulfilled the criteria for screening.  All 
children between the ages of 9-11years (n= 12/12) were recommended for screening based on age as 
per 2011 NHLBI guidelines, while 25% (n= 3/12) of the children aged 9-11 years fulfilled the criteria for 
targeted screening. 50% (n= 7/14) of those aged 12 or older fulfilled the criterion for screening as per 
guidelines.  
Overall 40% (n = 21/53) of patients surveyed met the criteria for targeted screening (11/27 aged up to 
9 years, 3/12 aged 9-11 years, and 7/14 aged 12-14 years), while 53% (n= 30/53) met the criteria for 
screening per the 2011 NHLBI guidelines when universal screening in all patients aged 9-11 years is 
taken into account.  
                                                      
 
 
If this is restricted on the basis of age to those aged 9 and over, 100% (n=26/26) would be screened 
on the basis of 2011 guidelines with 38% (n=10/26) screened on the basis of targeted screening.  
Parental Attitudes to Cholesterol analysis 
Fifty-two of those surveyed (98%) had no objection to the possibility of a cholesterol analysis being 
performed on their child. When those surveyed were asked regarding management of lipid issues, 
93% (n=49) stated they would be happy to receive advice from a dietician regarding management of 
dyslipidaemia. When asked regarding the possibility of cholesterol lowering medication being 
prescribed in the case of raised cholesterol, 58% (n=31) of parents surveyed expressed concerns such 
as lack of information, dietary preference and long-term medication effects (Table 1).  
 
Figure 1. Number of risk factors of included patients grouped by age. 
 
 
Figure 2. A breakdown of the risk factors identified in patients in each age range. 
 
                                                      
 
 
No. Parents Primary Concern listed by parent 
17% (n=9) Lack of information about statins 
11% (n=6) Prefer to exhaust dietary measures  
9% (n=5) Concerns about long term effects of statin medications being prescribed to their children 
4% (n=2) Only agreeable to statins as a last option 
17% (n=9) No reason given 
 
Table 1. Concerns from parents in relation to treating their child with a statin. 
 
Discussion 
Lipid disorders in the paediatric population are often missed 9 10, with previous research on selected 
screening demonstrates that as many as half of children with genetic and acquired cholesterol dis-
orders are missed in the absence of routine screening 6 11. NHLBI recommendations are aimed at 
providing screening to the whole paediatric population and this has not been previously studied or 
examined for feasibility. Our results showed that within this group 40% of children had at least one 
cardiovascular risk factor. This 40% met the criteria for targeted screening, and this increased to 53% 
when the 2011 NLHBI guidelines were applied. Additionally, further restriction to those aged 9 years 
and over where full population screening is advocated in the 2011 guidelines, resulted in 100% 
meeting the criteria for screening with only 38% meeting criteria on the basis of targeted screening. 
Thus, although a significant proportion of those surveyed have CVD risk factors, a large number of 
those surveyed would not be screened on the basis of targeted screening but would be included for 
screening based on the NLHBI guidelines.  
Prior to the 2011 NLHBI guidelines, groups such as  the American Academy of Paediatrics had 
guidelines which recommended screening with a fasting lipid profile for all children between 2 and 10 
years old with an identified positive family history or patient risk factors 12. However, in order for this 
type of selective screening program to work, the patients that meet screening criteria needed to be 
properly identified and there are no set standards for assessment of family histories, accurate blood 
pressure measurement and interpretation, and thus risk factor identification is in itself a difficult 
process to undertake. In addition, in order for any selective screening program to work, the screening 
criteria needs to be sensitive enough to detect affected patients. Unfortunately, for paediatric dys-
lipidaemias, significant evidence exists to indicate that using family history of premature CVD or 
cholesterol disorders as the primary factor in determining lipid screening for children misses between 
30% to 60% of children with dyslipidaemias, and accurate and reliable measures of family history are 
not available 11. 
Although universal screening of all children aged 9-11 years is the current recommendation in the 
American guidelines, there are no plans currently to introduce this screening in Ireland. There are cost 
implications for any screening policy. Additionally, the logistics of providing follow-up care and the 
uncertainty about the use of statins in children are concerns which would have to be dealt with. Given 
the high prevalence of CVD in adults in Ireland, there is a rationale for further and larger studies in 
populations of Irish children, but, notwithstanding, clinicians should consider screening and 
counselling for CVD risk factors in individual children who are known to have one or more CVD risk 
factor, albeit with the inherent limitations of risk factor screening as previously addressed.  
                                                      
 
 
In our study population, 98% of the study population had no issue with lipid testing being carried out, 
although a proportion (19%) expressed concern that lipid analysis would require additional 
phlebotomy. 93% of those surveyed were willing to receive advice from a dietician regarding 
management of dyslipidaemia, however, over half (58%) expressed concerns at the use of medications 
to treat dyslipidaemia. Professional advice regarding dietary modification and introduction of exercise 
are the key initial elements of tackling paediatric dyslipidaemias with family-based therapy 
recommended in order to achieve best results 8. It is encouraging that only 3/53 patients would object 
to a dietician consultation to initiate management of dyslipidaemia.  
To our knowledge, this is the first study of its kind in Ireland and its results are important in interpreting 
Irish cholesterol screening practices and parental attitudes, in an international context. The study, 
however, is not without limitations. The sample size used was small; 66 patients with 53 
questionnaires returned. We also evaluated only paediatric hospital in-patients, who are by definition 
currently of poor health. The responses within the questionnaire were self-reported and thus subject 
to recall bias. Although the questionnaire contained a section for height and weight, the reporting of 
these in the questionnaires was so low (<50%) that BMI could not be calculated. The study was 
questionnaire-based, and thus although parental concerns to screening were examined, a more 
comprehensive qualitative study would be required to fully appreciate parental expectations and 
concerns within this area. However, despite these limitations this study gives valuable insight into the 
potential and drawbacks associated with adoption of universal screening within an Irish context.  
Overall, dyslipidaemias are common and increasing within the paediatric setting and are frequently 
missed with selective screening, while the identification of CVD risk factors in children can be 
challenging and can be missed. The results from this study show that the use of targeted screening 
would miss a significant proportion that would be included on the basis of universal screening. Further 
studies are required to evaluate if routine or indeed targeted cholesterol screening may be 
appropriate to apply to the Irish child population.  
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